You are here: Industry Insights > alirocumab

News List

EU regulators expand Praluent’s label pharmatimes
March 19, 2019
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease firstwordpharma
March 18, 2019
The European Commission (EC) has approved a new indication for Praluent®(alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adj
New Cholesterol Drug, Alirocumab's (Praluent), High Price May Not Be Worth It: Study drugs
January 03, 2019
Despite being slashed by half in recent months, the price tag for advanced cholesterol-fighting drugs is still too high to make them cost-effective, a new analysis has concluded.....